epilepsy in pregnancy

in review 3 min read Updated 2026-10-18
epilepsy in pregnancy

Most stay seizure-free (~90% if seizure-free for 9–12 months pre-conception) . Lamotrigine and levetiracetam levels fall substantially → breakthrough seizures are often pharmacokinetic, not non-adherence — monitor levels and uptitrate, then taper postpartum to avoid toxicity. Avoid valproate (malformations + neurodevelopment) and topiramate where possible. Any new seizure ≥20 wk or postpartum = eclampsia until proven otherwise.

antiseizure medication choice (AAN/AES/SMFM 2024)

ASMpregnancynotes
lamotriginepreferredclearance ↑ up to 2–3× (glucuronidation) — TDM essential
levetiracetampreferredrenal clearance ↑ — TDM
oxcarbazepineacceptablelevels ↓ (monohydroxy derivative)
carbamazepineintermediatehigher MCM risk than LTG/LEV; NTD
topiramateavoid if possibleoral clefts, SGA
phenobarbitalavoid if possiblecardiac malformations (Level A), oral clefts
phenytoinintermediateMCM ~5% (very low certainty); no specific AAN avoid rec
valproateavoidMCM ~10% (dose-dependent), NTD, ↓IQ, autism — highest risk
  • Monotherapy at lowest effective dose; avoid polytherapy with higher-risk agents
  • Don’t stop or switch abruptly in an established pregnancy — a GTC seizure risks trauma, hypoxaemia, foetal compromise, SUDEP
  • Valproate in women of reproductive potential only if no alternative, with effective contraception (pregnancy prevention programme)

pre-conception

  • Confirm syndrome, seizure type, frequency, prior status epilepticus
  • Switch away from valproate/topiramate before conception (needs months to assess control)
  • Baseline ASM level when seizure-free = individual reference concentration
  • Folic acid ≥0.4 mg/d (AAN 2024); many Canadian centres use 1 mg (SOGC moderate-risk category) — higher doses not proven
  • Enzyme inducers (carbamazepine, phenytoin, topiramate >200 mg, oxcarbazepine) ↓ hormonal contraceptive efficacy → IUD or implant (not oral COC/POP)
  • Lamotrigine levels fall on oestrogen-containing contraception

during pregnancy

  • Levels (LTG, LEV, OXC) throughout pregnancy, guided by each ASM’s pharmacokinetics and clinical picture (AAN, Level B) — monthly is the practical default ; increase dose to keep at reference concentration
  • Breakthrough seizure → check level, sleep, vomiting, adherence; exclude eclampsia, CVST, hypoglycaemia, hyponatraemia
  • Detailed anatomy scan for any ASM; foetal echo if phenobarbital; serial growth scans if valproate or topiramate (FGR)
  • Status epilepticus: standard benzodiazepine → second-line (levetiracetam preferred) protocol; left lateral; if ≥20 wk add Mg if eclampsia possible
breakthrough seizures on lamotrigine

31 wk, adherent, breakthrough seizures on lamotrigine, level well below pre-pregnancy → increased glucuronidation. Increase dose (with neurology), exclude eclampsia/metabolic causes, and write the postpartum taper plan now.


labour, postpartum, breastfeeding

  • Continue ASMs throughout labour (IV levetiracetam/lacosamide if NPO); epilepsy alone ≠ CS indication
  • Avoid sleep deprivation — night support, expressed milk feeds
  • Postpartum: clearance normalises within 1–3 wk → reduce LTG stepwise over ~2–3 wk back toward pre-pregnancy dose (toxicity: dizziness, diplopia, ataxia)
  • Breastfeeding encouraged on LTG, LEV, OXC, CBZ, VPA — monitor infant for sedation, poor feeding (more with phenobarbital, benzodiazepines)
  • Safety: change nappies on floor, avoid bathing infant alone
  • Any in utero ASM exposure → age-appropriate developmental screening of the child

evidence

  • Background MCM rate in the general population ~2.4–2.9% (AAN 2024) — the counselling baseline
  • EURAP (2018) — MCM at 1 year: levetiracetam 2.8%, lamotrigine 2.9%, oxcarbazepine 3.0%, carbamazepine 5.5%, topiramate 3.9%, phenytoin 6.4%, phenobarbital 6.5%, valproate 10.3%; risk dose-dependent for carbamazepine, lamotrigine, phenobarbital, valproate

Prepared 2026-10-18. Not yet verified — check every number against the sources.

Key references

Suggest a correction epilepsy in pregnancy